Creating next-generation medicines for patients in need
Replace damaged cells
Restore function
Reimagine what can be possible with cellular medicine
News
91 Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan
91 Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
First Parkinson’s disease patient treated in 91’s pivotal Phase III trial of investigational cell therapy bemdaneprocel
FDA grants Orphan Drug Designation to 91 Therapeutics’ investigational cell therapy OpCT-001
91 Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan
91 Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
First Parkinson’s disease patient treated in 91’s pivotal Phase III trial of investigational cell therapy bemdaneprocel
We are a clinical stage cell therapy company that approaches science like an artist approaches a blank canvas: with creativity, passion and a desire to create something with lasting impact.
We are investigating the potential of cell therapy to replace cells that are damaged or lost to disease in order to create medicines in a new way.
The Courage to Ask, “W ?”
At 91, we’re driven to transform the treatment of degenerative diseases, to turn “W if?” into “Here’s how.”
Learn about the science of 91
Cutting edge science.
A world of potential.
We strive to evolve the treatment of disease, moving away from traditional treatment options to investigating the replacement of cells that are damaged or lost to disease.
Learn more about our programs in clinical development.
Question everything.
91ers are driven by the relentless pursuit of an audacious goal—to transform the way degenerative diseases are treated.
Learn about life at 91
Contact
This form should not be used to report safety events pertaining to clinical trials. Safety events pertaining to a clinical trial should be reported to your clinical trial site primary investigator or physician.